Skip to content

02563.HK

Beijing Biostar Pharms Co Ltd

HKSE · Healthcare · Drug Manufacturers - General · CN

HKD 3.72
−0.27%
Ask drillr

Year over year

Reported trailing growth

Revenue
EBITDA
EBIT
EPS
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
-0.2%
EBITDA
+19.5%
EBIT
+17.9%
Net income
+8.6%
EPS
+9.3%
Free cash flow
-7.0%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026